Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital

In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital.

Steven Boyd is the founder and Managing Partner of Armistice Capital, a hedge fund based in New York. Steven Boyd graduated with a B.S. in Economics as well as a B.A. in Political Science from The Wharton School of the University of Pennsylvania. He started his career as an Analyst at McKinsey & Company, followed by a stint as an Analyst at SAB Capital Management. Later, Steven worked as an Associate at York Capital, focusing primarily on investments in consumer and health care equities. Prior to forming Armistice Capital, Steven worked as a Senior Research Analyst at Senator Investment Group.

Armistice Capital is a global, long/short, value-oriented, and event-driven hedge fund primarily focused on healthcare and consumer sectors. The hedge fund predominantly invests in equities with rare opportunistic investments across the capital structure.

As of Q2 2022, the 13F portfolio of Steven Boyd’s Armistice Capital was valued at $5.7 billion. Some of the notable companies included in the portfolio were Illumina, Inc. (NASDAQ:ILMN), Medtronic plc (NYSE:MDT), Adobe Inc. (NASDAQ:ADBE), and Walmart Inc. (NYSE:WMT), among others.

Methodology

We picked the top 10 pharmaceutical stocks from Steven Boyd’s Armistice Capital 13F portfolio for the second quarter of 2022.

10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital

10. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Armistice Capital’s Stake Value: $87,918,000

Percentage of Armistice Capital’s 13F Portfolio: 1.53%

Number of Hedge Fund Holders: 45

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a pharmaceutical company focused on creation of transformative medicines for people with serious and life-threatening diseases. It discovered and developed the first medicines to treat the underlying cause of cystic fibrosis, a rare, life-threatening genetic disease.

Armistice Capital holds 312,000 shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), making up 1.53% of the hedge fund’s 13F portfolio. Armistice Capital’s stake in the company increased by 33% in Q2 2020, compared to the previous quarter.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly results for Q2 2022 in August. Its net revenue increased by 22% y-o-y to $2.2 billion, while it reported a net income of $810 million. It reported a normalized EPS of $3.60, beating the consensus by $0.10.

On September 27, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it had concluded talks with FDA and will submit its biologics licensing application for exa-cel for potential treatment of sickle cell disease and transfusion-dependent beta thalassemia for rolling review beginning in November.

As of Q2 2022, 45 hedge funds out of the 895 hedge funds tracked by Insider Monkey were bullish on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and held its shares valued at $2.3 billion. Jim Simons’ Renaissance Technologies was the largest shareholder holding 1.8 million shares valued at $496 million.

9. Bristol-Myers Squibb Company (NYSE:BMY)

Armistice Capital’s Stake Value: $89,012,000

Percentage of Armistice Capital’s 13F Portfolio: 1.55%

Number of Hedge Fund Holders: 69

Based in New Jersey, Bristol-Myers Squibb Company (NYSE:BMY) is a biotechnology company focused on the discovery, development, and delivery of innovative medicines for serious diseases across oncology, hematology, immunology, cardiovascular disease, and fibrosis.

Steven Boyd’s Armistice Capital owns 1,156,000 shares in Bristol-Myers Squibb Company (NYSE:BMY), accounting for 1.55% of the hedge fund’s 13F portfolio. The hedge fund reduced its investment in Bristol-Myers Squibb Company (NYSE:BMY) by 18% in Q2 2022, compared to the previous quarter.

Bristol-Myers Squibb Company (NYSE:BMY) shares have fared significantly better than the broader United States equity indices. It is up 14% year to date.

According to the Insider Monkey data tracking 895 hedge funds, 69 hedge funds were long Bristol-Myers Squibb Company (NYSE:BMY) as of Q2 2022, holding shares with total value of $2.2 billion. Its largest shareholder was Two Sigma Advisors with ownership of 4.7 million shares valued at $363 million.

8. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Armistice Capital’s Stake Value: $97,849,000

Percentage of Armistice Capital’s 13F Portfolio: 1.70%

Number of Hedge Fund Holders: 18

Watertown, Massachusetts-based Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a clinical stage biotechnology company focused on the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases.

Steven Boyd’s Armistice Capital owns 2,070,000 shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), accounting for 1.70% of its 13F portfolio. The hedge fund increased its stake by 85% in the company during Q2 2022, compared to the previous quarter.

The pipeline of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) includes clinical candidates currently in development for respiratory syncytial virus (RSV), COVID-19 and hepatitis B virus. It is also conducting research in human metapneumovirus.

On August 10, Oppenheimer analyst Jay Olson raised the price target on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares to $59 from $53 and maintained a ‘Perform’ rating on the shares.

As of Q2 2022, 18 of the 895 hedge funds tracked by Insider Monkey owned shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), valued at $263 million. Thomas Steyer’s Farallon Capital was its second largest shareholder after Armistice Capital, with ownership of 1.6 million shares valued at $73 million.

7. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Armistice Capital’s Stake Value: $111,132,000

Percentage of Armistice Capital’s 13F Portfolio: 1.93%

Number of Hedge Fund Holders: 44

Based in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company that invents, develops, and commercializes medicines with a focus on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.

Steven Boyd’s Armistice Capital owns 188,000 shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), accounting for 1.93% of its 13F portfolio. The hedge fund doubled down on its investment in the pharmaceutical company and increased its stake by 124% in Q2 2022, as compared to the previous quarter.

On September 28, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that it had received FDA approval for Dupixent for the treatment of adult patients with prurigo nodularis, a chronic, debilitating skin disease. Dupixent is the first and only medicine specifically indicated to treat this disease.

Earlier on September 16, Canaccord analyst John Newman had raised the price target for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares to $750 from $700 while maintaining a ‘Buy’ rating.

As of Q2 2022, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were held by 44 of the 895 hedge funds tracked by Insider Monkey, for a total value of $1.6 billion. Jim Simons’ Renaissance Technologies was the largest hedge fund shareholder, with ownership of 0.6 million shares valued at $345 million.

6. Travere Therapeutics, Inc. (NASDAQ:TVTX)

Armistice Capital’s Stake Value: $128,904,000

Percentage of Armistice Capital’s 13F Portfolio: 2.24%

Number of Hedge Fund Holders: 30

San Diego, California-based Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company focused on developing therapies for rare diseases. Its product portfolio comprises four approved drugs: Chenodal, Cholbam, Thiola, and Thiola EC delayed-release tablets, while its R&D pipeline is led by sparsentan – a novel product candidate targeting rare kidney diseases.

Steven Boyd’s Armistice Capital owns 5,320,000 shares of Travere Therapeutics, Inc. (NASDAQ:TVTX), accounting for 2.24% of its 13F portfolio. The hedge fund increased its stake by 8% in Q2 2022, as compared to the previous quarter.

In August, Travere Therapeutics, Inc. (NASDAQ:TVTX) announced the EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgAN, a rare kidney disorder, with potential approval expected in the second half of 2023.

On August 15, Piper Sandler analyst Do Kim lowered the price target on Travere Therapeutics, Inc. (NASDAQ:TVTX) shares to $39 from $41 while maintaining an ‘Overweight’ rating on the shares.

As of Q2 2022, 30 of the 895 hedge funds tracked by Insider Monkey were long Travere Therapeutics, Inc. (NASDAQ:TVTX), holding shares worth $704 million.

Click to continue reading and see 5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital.

Suggested Articles:

Disclosure: None. 10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!